Kumar Gaurav

About Kumar Gaurav

Most healthcare decisions aren’t limited by data — they’re limited by how we interpret it. I work at the intersection of health economics, advanced analytics, and clinical data, helping translate complex evidence into decisions that matter. My journey into Health Economics was shaped through my Master’s training across leading European institutions, including Erasmus University Rotterdam, University of Bologna, and University of Oslo. Studying across the Netherlands, Italy, and Norway exposed me to diverse healthcare systems, HTA frameworks, and payer perspectives, which continues to influence how I approach real-world decision-making problems today. Beyond analytics, I bring a strong commercial lens to my work. My experience in sales and marketing enables me to think beyond technical outputs and focus on: • Market access realities • Stakeholder and payer needs • Value communication and positioning This combination helps bridge a critical gap: • Not just building models, but making them relevant, actionable, and aligned with commercial strategy My core expertise lies in: • Health Economics & Outcomes Research (HEOR) • Survival Analysis & Time-to-Event Modeling • R Programming & Shiny-based tools • Network Meta-Analysis (NMA) • HTA-ready evidence generation I’ve worked extensively on oncology datasets, building models that go beyond statistical outputs and support payer, clinical, and policy decision-making. What I care about most: → Making complex models understandable → Bridging analytics with business and policy impact → Building scalable, reproducible solutions in R

Experience

1. Senior Analyst - Economic Modelling

   Novartis

   Sep 2023 — Present · IN

   Built and validated survival models for oncology datasets to support HTA and payer decision-making• Developed R-based workflows and Shiny applications to improve reproducibility and reduce analysis time• Interpreted complex statistical outputs into clear, decision-ready insights for cross-functional stakeholders• Supported evidence generation strategies aligned with market access and reimbursement requirements• Collaborated with clinical and commercial teams to ensure analytical outputs aligned with real-world business needs• Led development and launch of cost-effectiveness models for Neuroendocrine tumors and Prostate Cancer, establishing value propositions for payers and HTA bodies• Conducted advanced survival analyses for Radioligand Therapy portfolio using sophisticated crossover methodologies (IPCW, RPSFTM, TSA)• Designed comprehensive budget impact models incorporating epidemiological factors (incidence/prevalence) and competitive landscape analysis• Collaborated cross-functionally with evidence synthesis teams to ensure robust model inputs and methodological alignment• Created compelling value messaging for RLT portfolio, translating complex health economic outcomes into clear stakeholder communications• Developed tailored economic models addressing diverse patient demographics and market segments• Executed comprehensive market access assessments, identifying key barriers and opportunities for optimal product positioning• Engaged with external stakeholders to gather critical insights, ensuring economic models reflected real-world clinical and payer perspectives• Provided strategic recommendations that directly informed global market access and reimbursement strategies• Utilized advanced analytical tools including Excel, STATA, and R to deliver data-driven insights that supported commercial decision-making

Education

• Alma Mater Studiorum – Università di Bologna

  European Masters In Health Economics And Management, Health Economics

  2020 — 2022

• Erasmus University Rotterdam

  European Masters In Health Economics And Management, Health Economics

  2020 — 2022

• University of Oslo

  European Masters in Health Economics and Management, Economics Evaluation

  2020 — 2022

• Manipal Academy of Higher Education

  Bachelor of Pharmacy (BPharm), Pharmacy

  2010 — 2014